List of Regenerative Medicine Companies in Switzerland - 12

cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.

Our mission: to give patients back more of their own skin to make them well again. CUTISS is a Swiss clinical-stage life sciences company focussed on regenerative medicine, skin tissue engineering, and skin pigmentation. We are developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries. Our lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase 2 clinical trials in Switzerland and the European Union. It has Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. Our company’s knowledge in skin bio-engineering and biology offers other growth opportunities in regenerative medicine, and also beyond the medical domain. Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) / University Children’s Hospital. We successfully exited the Wyss Zurich accelerator in 2022. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over CHF 55 million from private investors, family offices and public bodies.

endogena’s mission is to discover and develop first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. our approach has the potential for a medical treatment paradigm change to effectively address unmet medical needs associated with ageing and genetic diseases. endogena therapeutics is implementing state-of-the art innovation in the field of regenerative medicine. our science combines the latest developments in stem cell biology, artificial intelligence and our expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. recent breakthroughs in stem cell biology together with technological advances for phenotypic, functional screening have unlocked our ability to harness the potential of adult stem- and precursor cells. our novel drug discovery approach is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules.

Exogems uses an FDA-approved medical device (Lipogems®) to produce exosomes from the mesenchymal stems cells in fat. They are developing methods for using these exosomes to deliver therapeutics.

Geistlich is a global leader dedicated to advancing regenerative medicine. Geistlich has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programs. Geistlich is a Swiss family-owned company with tradition since 1851. With 15 subsidiaries and 60 distributors, the company reaches around 90 markets and employs over 800 people. The ownership structure enables the company to plan long-term and to consistently develop innovative products. Geistlich Pharma AG continuously invests in developing its research and technology and relies on its qualified and specialized employees. Currently Geistlich Pharma is - the global market leader in regenerative dentistry - the leader in biological bone and cartilage regeneration - supplies drugs and medical devices in selected application areas

HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland. They are a preclinical stage company developing a therapeutic platform inspired by platelet biology.

MimiX biotherapeutics introduces Sound Induced Morphogenesis. We extend the boundaries of biofabrication, making bioengineered, artificial human organs and tissues a future reality. Sound Induced Morphogenesis (SIM) is a revolutionary approach in biofabrication. It mirrors nature’s design, to aggregate and pattern biologicals by tuning sound profiles under contactless, fast and delicate culture conditions resulting in a morphologically induced tissue generation. We introduce cymatiX®, a unique acoustic biofabrication solution that makes the Sound Induced Morphogenesis technology easily accessible to the scientific and clinical community Visit www.mimixbio.com to learn more. mimiX biotherapeutics is a Swiss biomedical company.

MPC Therapeutics is a biotechnology company focused on cellular rejuvenation to fight cancer & degenerative pathologies. They develop a class of compounds with applications in immunotherapy and metabolic diseases. The company is founded on the belief that they can manipulate cell behavior to fight cancer and degenerative diseases.

NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.

TissueLabs makes a platform for creating tissues and organs in the lab.

Volumina Medical is a multi-award-winning start-up active in the field of medical devices supported by a solid network of investors. The company develops breakthrough innovations for plastic and reconstructive surgery. The first product is an implantable polymeric biomaterial and targets the regeneration of soft tissue of the human body which are damaged after tumor excision, genetic malformation or trauma.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com